Pfizer Warns 'Troublesome' Price Hike Investigation Means Legal Uncertainty For Industry
This article was originally published in Scrip
The UK's Competition and Markets Authority has issued a provisional opinion finding that Pfizer and Flynn Pharma charged "excessive and unfair" prices for anti-epileptic phenytoin sodium capsules, rocketing the cost for the NHS. But Pfizer claims that it tried to find a profitable and sustainable way of providing the loss-making drug to the NHS, complaining that the CMA is creating greater legal uncertainty for companies.
You may also be interested in...
As the Mylan EpiPen controversy in the US draws yet more attention to price increases on certain pharmaceutical products, an imminent decision by the UK competition authorities should help to clarify what should constitute “excessive” and “unfair” pricing.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.